ESTUDO PREDIX (ASCO 2019) Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard


ESTUDO PREDIX (ASCO 2019) . ANALISE DE DESCALONAMENTO DE TRATAMENTO NEOADJUVANTE , COMPARANDO DOCETAXEL/TRAST+PERTUZ/ VERSUS TDM1 . 
RESULTADO FINAL SEM DIFERENÇA ESTATISTICA COM ALTAS TAXAS PARA SUBGRUPO DE RECEPTORES HORMONAIS NEGATIVO (HER-2 ENRICHED). NESTE ESTUDO FAZ SE  ANALISE EXPLORATORIA COMPARA-SE IMPORTANCIA DO PETCT , NA PCR .














Comentários

Postar um comentário

Postagens mais visitadas deste blog

Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis

http://www.nature.com/articles/srep06269 Abstract Epidermal growth factor receptor (EGFR) mutation is a reliable and sensitive biomarker for EGFR-TKI therapy in non-small-cell lung cancer (NSCLC). However, detection of EGFR mutation in tissues has obvious limitations. Circulating free DNA (cfDNA) has been reported as an alternative approach for the detection of EGFR mutations. This systematic review and meta-analysis was designed to assess the diagnostic performance of cfDNA, compared with tissues. True-positive (TP), false-positive (FP), false-negative (FN), and true-negative (TN) values were extracted or calculated for each study. Pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) were calculated. A summary receiver operating characteristic curve (SROC) and area under curve (AUC) were used to evaluate the overall diagnostic performance. 20 eligible studies involving 2012 cases were included in this m...
Leia mais